The MicroRNA Profile of Prostate Carcinoma Obtained by Deep Sequencing

  • Jaroslaw Szczyrba
    Authors' Affiliations: Departments of 1Virology, 2Urology, and 3Pathology, University of Saarland Medical School, Homburg/Saar, Germany; 4University Clinic of Urology and 5Department of Pathology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany; 6University Clinic of Urology, University Regensburg, Regensburg, Germany; and 7Nikolaus-Fiebiger-Center for Molecular Medicine, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany
  • Elke Löprich
    Authors' Affiliations: Departments of 1Virology, 2Urology, and 3Pathology, University of Saarland Medical School, Homburg/Saar, Germany; 4University Clinic of Urology and 5Department of Pathology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany; 6University Clinic of Urology, University Regensburg, Regensburg, Germany; and 7Nikolaus-Fiebiger-Center for Molecular Medicine, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany
  • Sven Wach
    Authors' Affiliations: Departments of 1Virology, 2Urology, and 3Pathology, University of Saarland Medical School, Homburg/Saar, Germany; 4University Clinic of Urology and 5Department of Pathology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany; 6University Clinic of Urology, University Regensburg, Regensburg, Germany; and 7Nikolaus-Fiebiger-Center for Molecular Medicine, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany
  • Volker Jung
    Authors' Affiliations: Departments of 1Virology, 2Urology, and 3Pathology, University of Saarland Medical School, Homburg/Saar, Germany; 4University Clinic of Urology and 5Department of Pathology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany; 6University Clinic of Urology, University Regensburg, Regensburg, Germany; and 7Nikolaus-Fiebiger-Center for Molecular Medicine, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany
  • Gerhard Unteregger
    Authors' Affiliations: Departments of 1Virology, 2Urology, and 3Pathology, University of Saarland Medical School, Homburg/Saar, Germany; 4University Clinic of Urology and 5Department of Pathology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany; 6University Clinic of Urology, University Regensburg, Regensburg, Germany; and 7Nikolaus-Fiebiger-Center for Molecular Medicine, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany
  • Stephanie Barth
    Authors' Affiliations: Departments of 1Virology, 2Urology, and 3Pathology, University of Saarland Medical School, Homburg/Saar, Germany; 4University Clinic of Urology and 5Department of Pathology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany; 6University Clinic of Urology, University Regensburg, Regensburg, Germany; and 7Nikolaus-Fiebiger-Center for Molecular Medicine, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany
  • Rainer Grobholz
    Authors' Affiliations: Departments of 1Virology, 2Urology, and 3Pathology, University of Saarland Medical School, Homburg/Saar, Germany; 4University Clinic of Urology and 5Department of Pathology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany; 6University Clinic of Urology, University Regensburg, Regensburg, Germany; and 7Nikolaus-Fiebiger-Center for Molecular Medicine, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany
  • Wolf Wieland
    Authors' Affiliations: Departments of 1Virology, 2Urology, and 3Pathology, University of Saarland Medical School, Homburg/Saar, Germany; 4University Clinic of Urology and 5Department of Pathology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany; 6University Clinic of Urology, University Regensburg, Regensburg, Germany; and 7Nikolaus-Fiebiger-Center for Molecular Medicine, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany
  • Robert Stöhr
    Authors' Affiliations: Departments of 1Virology, 2Urology, and 3Pathology, University of Saarland Medical School, Homburg/Saar, Germany; 4University Clinic of Urology and 5Department of Pathology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany; 6University Clinic of Urology, University Regensburg, Regensburg, Germany; and 7Nikolaus-Fiebiger-Center for Molecular Medicine, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany
  • Arndt Hartmann
    Authors' Affiliations: Departments of 1Virology, 2Urology, and 3Pathology, University of Saarland Medical School, Homburg/Saar, Germany; 4University Clinic of Urology and 5Department of Pathology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany; 6University Clinic of Urology, University Regensburg, Regensburg, Germany; and 7Nikolaus-Fiebiger-Center for Molecular Medicine, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany
  • Bernd Wullich
    Authors' Affiliations: Departments of 1Virology, 2Urology, and 3Pathology, University of Saarland Medical School, Homburg/Saar, Germany; 4University Clinic of Urology and 5Department of Pathology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany; 6University Clinic of Urology, University Regensburg, Regensburg, Germany; and 7Nikolaus-Fiebiger-Center for Molecular Medicine, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany
  • Friedrich Grässer
    Authors' Affiliations: Departments of 1Virology, 2Urology, and 3Pathology, University of Saarland Medical School, Homburg/Saar, Germany; 4University Clinic of Urology and 5Department of Pathology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany; 6University Clinic of Urology, University Regensburg, Regensburg, Germany; and 7Nikolaus-Fiebiger-Center for Molecular Medicine, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany

書誌事項

公開日
2010-04-01
DOI
  • 10.1158/1541-7786.mcr-09-0443
公開者
American Association for Cancer Research (AACR)

この論文をさがす

説明

<jats:title>Abstract</jats:title> <jats:p>Prostate cancer is a leading cause of tumor mortality. To characterize the underlying molecular mechanisms, we have compared the microRNA (miRNA) profile of primary prostate cancers and noncancer prostate tissues using deep sequencing. MiRNAs are small noncoding RNAs of 21 to 25 nucleotides that regulate gene expression through the inhibition of protein synthesis. We find that 33 miRNAs were upregulated or downregulated &gt;1.5-fold. The deregulation of selected miRNAs was confirmed by both Northern blotting and quantitative reverse transcription-PCR in established prostate cancer cell lines and clinical tissue samples. A computational search indicated the 3′-untranslated region (UTR) of the mRNA for myosin VI (MYO6) as a potential target for both miR-143 and miR-145, the expression of which was reduced in the tumor tissues. Upregulation of myosin VI in prostate cancer was previously shown by immunohistochemistry. The level of MYO6 mRNA was significantly induced in all primary tumor tissues compared with the nontumor tissue from the same patient. This finding was matched to the upregulation of myosin VI in established prostate cancer cell lines. In luciferase reporter analysis, we find a significant negative regulatory effect on the MYO6 3′UTR by both miR-143 and miR-145. Mutation of the potential binding sites for miR-143 and miR-145 in the MYO6 3′UTR resulted in a loss of responsiveness to the corresponding miRNA. Our data indicate that miR-143 and miR-145 are involved in the regulation of MYO6 expression and possibly in the development of prostate cancer. Mol Cancer Res; 8(4); 529–38. ©2010 AACR.</jats:p>

収録刊行物

  • Molecular Cancer Research

    Molecular Cancer Research 8 (4), 529-538, 2010-04-01

    American Association for Cancer Research (AACR)

被引用文献 (8)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ